Literature DB >> 32172996

Incident cardiovascular disease in patients diagnosed with multiple sclerosis: A multi-database study.

Rebecca Persson1, Sally Lee2, Marianne Ulcickas Yood3, Michael Wagner4, Neil Minton2, Steve Niemcryk2, Anders Lindholm2, Amber Evans5, Susan Jick6.   

Abstract

BACKGROUND: Recent data on rates of cardiovascular disease (CVD) in patients after MS diagnosis are sparse.
OBJECTIVE: To describe incident CVD in MS patients after diagnosis compared with a matched non-MS population.
METHODS: We conducted a matched cohort study in two separate electronic medical databases, the United States Department of Defense military health care system and the United Kingdom's Clinical Practice Research Datalink GOLD. The study population included all patients with a first recorded diagnosis of MS and no history of CVD or selected measurable comorbidities associated with CVD and matched non-MS patients who were also free of CVD and the CVD associated comorbidities. We identified incident CVD outcomes first recorded after the MS diagnosis / matched date and calculated incidence rates and incidence rate ratios by type of CVD.
RESULTS: Rates of venous thromboembolism and peripheral vascular disease were 2-fold higher among MS than non-MS patients in both databases and the risk of myocardial infarction was 2.5 times higher among female MS patients compared with non-MS females in both databases. Other CVD outcomes were not consistent between databases.
CONCLUSION: MS patients in the UK and the US have increased risk of venous thromboembolism and peripheral vascular disease. The risk of myocardial infarction is increased among female MS patients.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Cardiovascular disease; Incidence; Multiple sclerosis; Myocardial infarction; Peripheral vascular diseases; Venous thromboembolism

Year:  2019        PMID: 32172996     DOI: 10.1016/j.msard.2019.101423

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  7 in total

1.  Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden.

Authors:  Anna Castelo-Branco; Flaminia Chiesa; Camilla E Bengtsson; Sally Lee; Neil N Minton; Steve Niemcryk; Anders Lindholm; Mats Rosenlund; Fredrik Piehl; Scott Montgomery
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-08-14

Review 2.  Proteomics in Multiple Sclerosis: The Perspective of the Clinician.

Authors:  Dániel Sandi; Zsófia Kokas; Tamás Biernacki; Krisztina Bencsik; Péter Klivényi; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

3.  Is multiple sclerosis a risk factor for infections?

Authors:  Jeannette Lechner-Scott; Emmanuelle Waubant; Michael Levy; Chris Hawkes; Gavin Giovannoni
Journal:  Mult Scler Relat Disord       Date:  2020-05-07       Impact factor: 4.339

Review 4.  The Canadian Women's Heart Health Alliance ATLAS on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women-Chapter 2: Scope of the Problem.

Authors:  Shahin Jaffer; Heather J A Foulds; Monica Parry; Christine A Gonsalves; Christine Pacheco; Marie-Annick Clavel; Kerri A Mullen; Cindy Y Y Yip; Sharon L Mulvagh; Colleen M Norris
Journal:  CJC Open       Date:  2020-10-15

5.  The Molecular Aspects of Disturbed Platelet Activation through ADP/P2Y12 Pathway in Multiple Sclerosis.

Authors:  Angela Dziedzic; Elzbieta Miller; Joanna Saluk-Bijak; Marta Niwald; Michal Bijak
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

6.  Perfect Storm: COVID-19 Associated Cardiac Injury and Implications for Neurological Disorders.

Authors:  Catherine Ruth Jutzeler; Thomas Edward Nightingale; Andrei Vasilievich Krassioukov; Matthias Walter
Journal:  Neurotrauma Rep       Date:  2020-07-23

7.  Increased Pro-Thrombotic Platelet Activity Associated with Thrombin/PAR1-Dependent Pathway Disorder in Patients with Secondary Progressive Multiple Sclerosis.

Authors:  Angela Dziedzic; Elzbieta Miller; Michal Bijak; Lukasz Przyslo; Joanna Saluk-Bijak
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.